Want to see NCEL full AI Analyst Report?
Top Page
NewcelX
(NASDAQ:NCEL)
Select Model
Select Model
Rating:45Neutral
Price Target:
$3.00
â–¼(-10.45% Downside)
Action:Reiterated
Date:10/17/26
The score is weighed down primarily by weak financial performance (zero revenue, recurring losses, and persistent negative free cash flow) and bearish technical trends (price below key moving averages with negative MACD). A low P/E provides some valuation support, but it is not enough to offset the fundamental cash-burn and lack-of-revenue risks.
Positive Factors
Low leverage
Modest debt relative to equity limits immediate balance-sheet leverage and interest burden, giving NewcelX some financial flexibility while it develops its programs. This cushion does not offset losses, but it reduces the near-term risk that debt service alone constrains operations.
Negative Factors
No revenue
Persistent zero revenue shows that NewcelX has not yet established commercial operating scale or an internally funded business model. Until revenue emerges, the company must rely on financing and development progress to support operations, leaving earnings power unproven.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Modest debt relative to equity limits immediate balance-sheet leverage and interest burden, giving NewcelX some financial flexibility while it develops its programs. This cushion does not offset losses, but it reduces the near-term risk that debt service alone constrains operations.
Read all positive factors
NewcelX (NCEL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.54M
Dividend YieldN/A
Average Volume (3M)6.93K
Price to Earnings (P/E)8.2
Beta (1Y)0.89
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,383,871
10 Day Avg. Volume10,932
30 Day Avg. Volume6,928
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-2.63
Enterprise Value/Market Cap-113.84K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit71.95M
Enterprise Value/Ebitda589.34K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NewcelX Business Overview & Revenue Model
Company Description
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and sm...
NewcelX Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -23.00K | 0.00 | -3.32K | -11.41K | -11.41K | -10.05K |
| EBITDA | -2.81M | -2.24M | -3.63M | -11.80M | -15.47M | -11.85M |
| Net Income | 1.45M | -8.30M | -1.98M | -12.17M | -16.50M | -11.95M |
Balance Sheet | ||||||
| Total Assets | 9.70M | 11.45M | 2.23M | 1.85M | 9.28M | 5.76M |
| Cash, Cash Equivalents and Short-Term Investments | 710.00K | 2.20M | 1.67M | 897.68K | 8.95M | 5.43M |
| Total Debt | 392.00K | 355.00K | 0.00 | 1.63M | 0.00 | 0.00 |
| Total Liabilities | 3.66M | 4.20M | 826.76K | 10.68M | 6.00M | 5.22M |
| Stockholders Equity | 6.04M | 7.25M | 1.41M | -8.83M | 3.28M | 542.39K |
Cash Flow | ||||||
| Free Cash Flow | -2.87M | -2.77M | -4.27M | -9.68M | -13.88M | -14.98M |
| Operating Cash Flow | -2.87M | -2.77M | -4.27M | -9.68M | -13.88M | -14.94M |
| Investing Cash Flow | 1.70K | 1.70M | -3.92K | 0.00 | -3.51M | -39.56K |
| Financing Cash Flow | 1.37M | 2.63M | 5.04M | 1.63M | 17.40M | 20.34M |
NewcelX Technical Analysis
Negative
3.35
Price Trends
3.05
Negative
3.32
Negative
3.10
Negative
Market Momentum
-0.12
Negative
46.00
Neutral
38.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NCEL, the sentiment is Negative. The current price of 3.35 is above the 20-day moving average (MA) of 2.79, above the 50-day MA of 3.05, and above the 200-day MA of 3.10, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 46.00 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NCEL.
NewcelX Risk Analysis
NewcelX disclosed 162 risk factors in its most recent earnings report. NewcelX reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NewcelX Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
NewcelX Corporate Events
NewcelX Files First-Half 2026 Results, Showing Wider Losses and Lower Cash
Sep 18, 2026
NewcelX Ltd. filed a Form 6-K on September 18, 2026, furnishing unaudited interim consolidated financial statements and management’s discussion and analysis for the six months ended June 30, 2026. The filing also includes Inline XBRL data to...
NewcelX Lines Up $1.4 Million Private Placement to Advance Type 1 Diabetes Program
Aug 3, 2026
On July 31, 2026, NewcelX Ltd. entered into securities purchase agreements for a private placement with accredited investors, covering 347,134 common shares or pre‑funded warrants at $4.033 per share and five‑year common warrants for t...
NewcelX Prices $1.4 Million Premium Equity Financing to Advance Type 1 Diabetes Cell Therapy
Jul 31, 2026
On July 31, 2026, NewcelX announced that it had entered into securities purchase agreements for a $1.4 million private equity financing, pricing 347,134 common shares at $4.033 per share, a 20% premium to the prior closing price, along with warran...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.